USA Tumor Embolization Report

September 2022

The USA Tumor Embolization report is the first ever syndicated report that covers the market landscape, procedural and technology trends, and competitive intelligence. The report is based on exhaustive secondary research and in-depth primary research conducted with performing physicians in Interventional Radiology departments from Academic Hospitals, Community Hospitals, Office Based Labs (OBL) and Private Hospitals in USA.

The report covers:

Tumor embolization devices: Bland embolization/transarterial chemoembolization, DEB-TACE, Radio Embolization (Y90), Coil/Microcoil embolization, nBCA or Onyx.
Procedure trends: cancer type and modality/device type.

“Improved imaging capabilities, being able to see the product, why you are doing embolization or see where it went after the embolization on cross-sectional imaging as a confirmation to ensure this is where we delivered our embolics. I think that will be a major change and then additionally different sizes of products that have demonstrated benefit, and if it is better to use 300-500 microns or less you know that has still not being answered yet completely.”

– Interventional Radiologist, Tumor Embolization US

>60% of interventional oncology procedures are conducted at University Hospitals
~45% of all tumor embolization procedures are performed for liver cancer
~25% of tumor embolization procedures are performed using bland embolization/TACE

Physicians’ brand perception and their rank of medical device companies based on 15 KPIs such as technology, clinical evidence, patient outcome, etc. Moreover, diligent examination of physician’s brand usage and brand satisfaction levels, and the factors such as ease of use of the device, and cost-effectiveness among others effecting brand usage have been covered.Future trends such as the immunotherapy used in combination with embolization technologies is gaining prominence. Expanded indications of embolization to treat cancer types such as prostate cancer and cholangiocarcinoma is expected to increase as clinical evidence suggests good patient outcomes.
Competitor landscape covers market events such as emerging companies, product approvals, clinical trials, partnerships etc. Competitor activities such Fluidx Medical’s GPX embolic device’s repeated success in treating complex tumors including a recent case for renal tumor at Christchurch hospital in New Zealand; GPX embolic device being under development, not having marketing clearance or approval in any market at this time and being available for investigational use only in New Zealand are covered in the report.

What’s in it for you?

This report will help tumor embolization devices companies understand the interventional oncology landscape, procedural and technology trends, the brand perception, and competitor activities in the USA.
The report is a great resource to plan your market strategy to capitalize on upcoming trends and potential disruptors in the tumor embolization devices market.

The deliverable includes a 100+ slide MS PowerPoint report and an MS Excel-based 5-Year market forecast model.
REPORT COST: 5,000 USD
Contact us below for further details regarding the exclusive data and insights in the report or for an exploratory analyst walkthrough of the report.

The United States Tumor Embolization Landscape, Procedure and Technology Trends, Brand Perception, Competitive Intelligence and Future Outlook (2019-2022)

Privacy settings